Glaxosmithkline PLC, Director at Turning Point Therapeutics, Inc. (TPTX), bought 83,333 shares at $60.00 ($5.0M) on 2020-05-21, disclosed to the SEC on 2020-05-26.
Open-market purchase of $5.0M TPTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| DBTX | BUY | 2021-02-19 | $2.7M | — | Filing → |
| BCYC | SELL | 2020-09-18 | $151K | — | Filing → |
| GNCA | BUY | 2020-07-30 | $2.8M | — | Filing → |